Drug intelligence / Profile preview

eprolidone

Development stage: Unknown
Administration: Oral

Overview

Eprolidone is a drug currently under investigation for the treatment of chronic heart failure. It is believed to exert an immunomodulatory effect by influencing the activity of regulatory T cells (Treg). This mechanism aims to improve drug efficacy, avoid ineffective treatments, and reduce adverse reactions in patients with chronic heart failure.

Other names: epridone

Beyond the preview

Go deeper on eprolidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eprolidone.